Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Second Sight Medical Products (EYES) Stock Price

News articles about Second Sight Medical Products (NASDAQ:EYES) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 44.5075168734894 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Second Sight Medical Products (NASDAQ EYES) opened at $1.91 on Friday. Second Sight Medical Products has a 1-year low of $0.90 and a 1-year high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings data on Thursday, November 2nd. The medical device company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. The company had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $1.54 million. Second Sight Medical Products had a negative return on equity of 184.87% and a negative net margin of 565.12%. equities research analysts forecast that Second Sight Medical Products will post -0.55 EPS for the current year.

A number of analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Second Sight Medical Products in a research report on Monday, November 6th. Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Wednesday, September 13th.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Second Sight Medical Products (EYES) Stock Price” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply